synthetic peptide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-08-21. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Lyophilized peptide; protect from moisture and light. |
| Typical analytical method | HPLC and mass spectrometry | Used to confirm identity and estimate purity. |
| Common synonyms | AOD9604; hGH 176-191 | Naming varies by supplier and publication. |
| Disulfide bonds | One | Affects folded structure and stability. |
| Typical research purity | ≥95% | Value depends on supplier and analytical method. |
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
=== Cellulose nanofiber plate === A bottom up approach can be used to create a high-performance bulk material with low density, high strength and toughness, and great thermal dimensional stability: cellulose nanofiber plate (CNFP). Cellulose nanofiber hydrogel is created by biosynthesis. The hydrogels can then be treated with a polymer solution or by surface modification and then are hot-pressed at 80 °C. The result is bulk material with excellent machinability. "The ultrafine nanofiber network structure in CNFP results in more extensive hydrogen bonding, the high in-plane orientation, and "three way branching points" of the microfibril networks". This structure gives CNFP its high strength by distributing stress and adding barriers to crack formation and propagation. The weak link in this structure is bond between the pressed layers which can lead to delamination. To reduce delamination, the hydrogel can be treated with silicic acid, which creates strong covalent cross-links between layers during hot pressing.
==== Other members ==== Octian Porupo (オクト星人ポルポ, Okuto Seijin Porupo): An octopus-themed member of S.P.D., and Ban's former instructor from Planet Octo, who feels his student should be removed from S.P.D. due to his recklessness. Porupo is voiced by Issei Futamata (二又 一成, Futamata Issei). Horusian Numa-O (ホルス星人ヌマ・O, Numa Ō): The professional avian supreme commander of S.P.D. from Planet Horus. Numa-O is voiced by Kazuhiko Kishino (岸野 一彦, Kishino Kazuhiko). Tortorian Buntar (トート星人ブンター, Tōto Seijin Buntā): An ape-themed member of S.P.D., and old friend of Kruger's, from Planet Torto, who owns a mechanical dog named Clarence K-9 (クラレンスK9, Kurarensu Kē Nain) and trains the Dekarangers to assume their S.W.A.T. Modes. Buntar is voiced by Naoki Kusumi (楠見 尚己, Kusumi Naoki). Lumierian Lisa Teagle (リュミエル星人リサ・ティーゲル, Ryumieru Seijin Risa Tīgeru): The chief of the Tokkyou Division's first squad from Planet Lumiere, and Tetsu's mentor, who believes that the perfect officer must be passionless to be efficient. Additionally, using her own Bracerottle, she can transform into the silver-colored Deka Bright (デカブライト, Deka Buraito). After coming to Earth, she initially intended to take Tetsu back for straying from her teachings, but decides against that after seeing him fight, realizing that passion can be a positive trait for an officer. Lisa Teagle is portrayed by Mie Nanamori (七森 美江, Nanamori Mie).
== Development history == Bimagrumab was developed by Novartis, in collaboration with Morphosys. On August 20, 2013, it was announced that bimagrumab had received a breakthrough therapy designation for sporadic inclusion body myositis (sIBM) by the US Food and Drug Administration (FDA). In 2014, Bimagrumab entered Phase II development, with some research indicating clinical effects. Novartis planned to apply in 2016 for FDA approval to treat sIBM patients with bimagrumab. In April 2016, Novartis announced that bimagrumab had failed a Phase IIb/III study for sporadic inclusion body myositis. In January 2021, a new study confirmed that treatment with bimagrumab is safe and effective for treating excess adiposity and metabolic disturbances of adult patients with obesity and type 2 diabetes. Novartis then licensed the drug to Versanis Bio, a Medicxi Fund and Atlas Venture-backed startup, who closed a series A financing round to fund a phase II clinical program targeting weight loss in obese patients. In January 2023 Versanis Bio entered the medication into phase IIb trials for obesity. In July 2023, Eli Lilly bought Versanis Bio for their weight loss asset for $1.9 billion. In 2025, a phase IIb study was concluded testing bimagrumab in combination with Novo Nordisk's semaglutide, demonstrating that the combination resulted in a greater loss of fat as a percentage of weight compared to semaglutide alone. In September 2025, Eli Lilly terminated a phase IIb study investigating a tirzepatide-bimagrumab combination in obese and type II diabetic patients.
== History == The chemical class of barbiturates are one of the oldest sedative-hypnotic agents known, dating back from the introduction of barbital in the early 20th century. In Hungary, hexobarbital (and other barbiturates) were regularly used as drugs by pregnant women attempting suicide. Hexobarbital was long thought to have potentially teratogenic and fetotoxic effects. The FDA has classified them as Pregnancy Category D or C. Some research however, indicate that ingestion of Hexobarbital might cause congenital abnormalities. During World War II, Herta Oberheuser was a Nazi physician and convicted war criminal, investigating the effects of hexobarbital. The experiments were mostly performed on woman prisoners in the Ravensbrück concentration camp.
Sources: en.wikipedia.org
This scaffold and cells were placed in a bioreactor, where it matured to become a partially or fully transplantable organ. the work was called a "landmark". The lab first stripped the cells away from a rat heart (a process called "decellularization") and then injected rat stem cells into the decellularized rat heart. Tissue-engineered blood vessels: Blood vessels that have been grown in a lab and can be used to repair damaged blood vessels without eliciting an immune response. Tissue engineered blood vessels have been developed by many different approaches. They could be implanted as pre-seeded cellularized blood vessels, as acellular vascular grafts made with decellularized vessels or synthetic vascular grafts. Artificial skin constructed from human skin cells embedded in a hydrogel, such as in the case of bio-printed constructs for battlefield burn repairs. Artificial bone marrow: Bone marrow cultured in vitro to be transplanted serves as a "just cells" approach to tissue engineering. Tissue engineered bone: A structural matrix can be composed of metals such as titanium, polymers of varying degradation rates, or certain types of ceramics. Materials are often chosen to recruit osteoblasts to aid in reforming the bone and returning biological function. Various types of cells can be added directly into the matrix to expedite the process. Laboratory-grown penis: Decellularized scaffolds of rabbit penises were recellularised with smooth muscle and endothelial cells.
=== Other pharmaceuticals === In 2017, a two-dose HBV vaccine for adults, the hepatitis B vaccine Heplisav-B gained U.S. Food and Drug Administration (FDA) approval. It uses recombinant HB surface antigen, similar to previous vaccines, but includes a novel CpG 1018 adjuvant, a 22-mer phosphorothioate-linked oligodeoxynucleotide. It was non-inferior concerning immunogenicity. Phosphorothioate groups are also used in synthetic CpG oligodeoxynucleotides.
=== Initial chemical classification === In the periodic table published by Dmitri Mendeleev in 1869, thorium and the rare-earth elements were placed outside the main body of the table, at the end of each vertical period after the alkaline earth metals. This reflected the belief at that time that thorium and the rare-earth metals were divalent. With the later recognition that the rare earths were mostly trivalent and thorium was tetravalent, Mendeleev moved cerium and thorium to group IV in 1871, which also contained the modern carbon group (group 14) and titanium group (group 4), because their maximum oxidation state was +4. Cerium was soon removed from the main body of the table and placed in a separate lanthanide series; thorium was left with group 4 as it had similar properties to its supposed lighter congeners in that group, such as titanium and zirconium.
Shortcomings of the sequence database searching workflow Due to the complex nature of peptide fragmentation in a mass spectrometer, derivative fragmentation patterns fall short of reproducing experimental mass spectra, especially relative intensities among distinct fragments. Thus, sequence database searching faces a bottleneck of limited specificity. Sequence database searching also demands vast search space, which still could not cover all possibilities of peptide dynamics, exhibiting limited efficiency post-translational modifications). The search process is sometimes slow and requires costly high-performance computers. In addition, the nature of sequence database searching disconnects the research discoveries among different groups or at different times.
While the galectin family as a whole has been widely recognized to be on the cell surface, the study of galectin's role in healing skin wounds is still being developed for therapeutic courses of action. Galectin-7 specifically promotes the re-epithelialization of the skin, kidney, corneal, and uterine wounds. While this protein is known for its role in epithelial homeostasis and apoptosis, it also functions as a modulator of adaptive immune responses within stratified epithelial tissues like the skin, cornea, and mucous areas. It has immunological effects that are derived from extracullar and intracellular roles like glycan binding. The response to damage and stress can modulate the secretion of epithelial-derived cytokines and promotion of immune activation or decreasing it. The enhancement of early inflammatory responses, regulation of cytokine secretion, modulation of immune-cell adhesion, apoptosis control, and altered immune landscapes in tumors are all local modulations of functions in epithelial stress responses to modulate immunity.
Sources: en.wikipedia.org
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.
The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.
It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.